MMP2 and inflammatory breast carcinoma: Inconsistent with our results, Tabouret et al. found that a high level of serum MMP-2 was associated with better disease-free survival and overall survival in patients with HER2(+) inflammatory breast cancer who were treated with bevacizumab and trastuzumab, as compared with those with low serum MMP-2 [17].